Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Liver Cirrhosis

  Free Subscription

Articles published in PLoS One

Retrieve available abstracts of 306 articles:
HTML format

Single Articles

    January 2021
  1. FRANKOVA S, Lunova M, Gottfriedova H, Senkerikova R, et al
    Liver stiffness measured by two-dimensional shear-wave elastography predicts hepatic vein pressure gradient at high values in liver transplant candidates with advanced liver cirrhosis.
    PLoS One. 2021;16:e0244934.
    PubMed     Abstract available

  2. YEN YH, Cheng YF, Wang JH, Lin CC, et al
    Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West.
    PLoS One. 2021;16:e0244939.
    PubMed     Abstract available

  3. CHENG K, Liu W, You J, Shah S, et al
    Safety of laparoscopic pancreaticoduodenectomy in patients with liver cirrhosis using propensity score matching.
    PLoS One. 2021;16:e0246364.
    PubMed     Abstract available

  4. HOSHI H, Chu PS, Yoshida A, Taniki N, et al
    Vulnerability to recurrent episodes of acute decompensation/acute-on-chronic liver failure characterizes those triggered by indeterminate precipitants in patients with liver cirrhosis.
    PLoS One. 2021;16:e0250062.
    PubMed     Abstract available

  5. PEREIRA R, Buglevski M, Perdigoto R, Marcelino P, et al
    Intra-abdominal hypertension and abdominal compartment syndrome in the critically ill liver cirrhotic patient-prevalence and clinical outcomes. A multicentric retrospective cohort study in intensive care.
    PLoS One. 2021;16:e0251498.
    PubMed     Abstract available

  6. FERSTL PG, Filmann N, Heilgenthal EM, Schnitzbauer AA, et al
    Colonization with multidrug-resistant organisms is associated with in increased mortality in liver transplant candidates.
    PLoS One. 2021;16:e0245091.
    PubMed     Abstract available

  7. CHA HJ, Hwang J, Lee LE, Park Y, et al
    The significance of cytoplasmic antinuclear antibody patterns in autoimmune liver disease.
    PLoS One. 2021;16:e0244950.
    PubMed     Abstract available

  8. CARTER JK, Bhattacharya D, Borgerding JN, Fiel MI, et al
    Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales.
    PLoS One. 2021;16:e0244763.
    PubMed     Abstract available

  9. JO HH, Min C, Kyoung DS, Park MA, et al
    Adverse outcomes after surgeries in patients with liver cirrhosis among Korean population: A population-based study.
    PLoS One. 2021;16:e0253165.
    PubMed     Abstract available

  10. DUAH A, Agyei-Nkansah A, Osei-Poku F, Duah F, et al
    Sociodemographic characteristics, complications requiring hospital admission and causes of in-hospital death in patients with liver cirrhosis admitted at a district hospital in Ghana.
    PLoS One. 2021;16:e0253759.
    PubMed     Abstract available

  11. LEE JW, Hwang JS, Chung WJ, Lee HJ, et al
    Diagnostic usefulness of the spot urine sodium/potassium ratio in cirrhotic patients with ascites.
    PLoS One. 2021;16:e0253886.
    PubMed     Abstract available

    January 2020
  12. CHEN Q, Wu X, Zhang D
    Comparison of the abilities of universal, super, and specific DNA barcodes to discriminate among the original species of Fritillariae cirrhosae bulbus and its adulterants.
    PLoS One. 2020;15:e0229181.
    PubMed     Abstract available

  13. DIAZ-RIVERA A, Meza-Rios A, Chagoya de Sanchez V, Velasco-Loyden G, et al
    Hydrodynamics-based liver transfection achieves gene silencing of CB1 using short hairpin RNA plasmid in cirrhotic rats.
    PLoS One. 2020;15:e0228729.
    PubMed     Abstract available

  14. PHILIP G, Djerboua M, Carlone D, Flemming JA, et al
    Validation of a hierarchical algorithm to define chronic liver disease and cirrhosis etiology in administrative healthcare data.
    PLoS One. 2020;15:e0229218.
    PubMed     Abstract available

  15. MOON AM, Jiang Y, Rogal SS, Becker J, et al
    In inpatients with cirrhosis opioid use is common and associated with length of stay and persistent use post-discharge.
    PLoS One. 2020;15:e0229497.
    PubMed     Abstract available

  16. CHANG TS, Tsai YH, Lin YH, Chen CH, et al
    Limited effects of antibiotic prophylaxis in patients with Child-Pugh class A/B cirrhosis and upper gastrointestinal bleeding.
    PLoS One. 2020;15:e0229101.
    PubMed     Abstract available

  17. HAUKELAND JW, Smastuen MC, Palsdatter PP, Ismail M, et al
    Effect of gender on mortality and causes of death in cirrhotic patients with gastroesophageal varices. A retrospective study in Norway.
    PLoS One. 2020;15:e0230263.
    PubMed     Abstract available

  18. LIN Y, Li H, Jin C, Wang H, et al
    The diagnostic accuracy of liver fibrosis in non-viral liver diseases using acoustic radiation force impulse elastography: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0227358.
    PubMed     Abstract available

  19. PAZGAN-SIMON M, Kukla M, Zuwala-Jagiello J, Derra A, et al
    Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC).
    PLoS One. 2020;15:e0227459.
    PubMed     Abstract available

  20. SHAO LN, Zhang ST, Wang N, Yu WJ, et al
    Platelet indices significantly correlate with liver fibrosis in HCV-infected patients.
    PLoS One. 2020;15:e0227544.
    PubMed     Abstract available

  21. BENZ F, Bogen A, Praktiknjo M, Jansen C, et al
    Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis.
    PLoS One. 2020;15:e0231701.
    PubMed     Abstract available

  22. MATSUMOTO M, Yashiro H, Ogino H, Aoyama K, et al
    Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.
    PLoS One. 2020;15:e0228212.
    PubMed     Abstract available

  23. WAKE T, Tateishi R, Fukumoto T, Nakagomi R, et al
    Improved liver function in patients with cirrhosis due to chronic hepatitis C virus who achieve sustained virologic response is not accompanied by increased liver volume.
    PLoS One. 2020;15:e0231836.
    PubMed     Abstract available

  24. SIRINAWASATIEN A, Techasirioangkun T
    Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
    PLoS One. 2020;15:e0229517.
    PubMed     Abstract available

  25. FORTEA JI, Puerto M, Fernandez-Mena C, Asensio I, et al
    Sevoflurane versus ketamine+diazepam anesthesia for assessing systemic and hepatic hemodynamics in rats with non-cirrhotic portal hypertension.
    PLoS One. 2020;15:e0233778.
    PubMed     Abstract available

  26. STOCKHOFF L, Schultalbers M, Tergast TL, Hinrichs JB, et al
    Safety and feasibility of transjugular intrahepatic portosystemic shunt in elderly patients with liver cirrhosis and refractory ascites.
    PLoS One. 2020;15:e0235199.
    PubMed     Abstract available

  27. DIEDRICH T, Kummer S, Galante A, Drolz A, et al
    Characterization of the immune cell landscape of patients with NAFLD.
    PLoS One. 2020;15:e0230307.
    PubMed     Abstract available

  28. RASHIDI-ALAVIJEH J, Ceylan AS, Wedemeyer H, Kleefisch M, et al
    Standard coagulation tests are superior to thromboelastometry in predicting outcome of patients with liver cirrhosis.
    PLoS One. 2020;15:e0236528.
    PubMed     Abstract available

  29. POILIL SURENDRAN S, George Thomas R, Moon MJ, Park R, et al
    Effect of hepato-toxins in the acceleration of hepatic fibrosis in hepatitis B mice.
    PLoS One. 2020;15:e0232619.
    PubMed     Abstract available

  30. HE L, Yuan H, Liang J, Hong J, et al
    Expression of hepatic stellate cell activation-related genes in HBV-, HCV-, and nonalcoholic fatty liver disease-associated fibrosis.
    PLoS One. 2020;15:e0233702.
    PubMed     Abstract available

  31. BAEZA-RAJA B, Goodyear A, Liu X, Lam K, et al
    Pharmacological inhibition of P2RX7 ameliorates liver injury by reducing inflammation and fibrosis.
    PLoS One. 2020;15:e0234038.
    PubMed     Abstract available

  32. ROGAL SS, Yakovchenko V, Gonzalez R, Park A, et al
    Characterizing patient-reported outcomes in veterans with cirrhosis.
    PLoS One. 2020;15:e0238712.
    PubMed     Abstract available

  33. SANTOIEMMA PP, Dakwar O, Angarone MP
    A retrospective analysis of cases of Spontaneous Bacterial Peritonitis in cirrhosis patients.
    PLoS One. 2020;15:e0239470.
    PubMed     Abstract available

  34. TABU K, Mawatari S, Oda K, Kumagai K, et al
    Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
    PLoS One. 2020;15:e0237475.
    PubMed     Abstract available

  35. CHEN K, Sng WK, Quah JH, Liu J, et al
    Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus.
    PLoS One. 2020;15:e0236977.
    PubMed     Abstract available

  36. AN J, Kim HI, Chang S, Shim JH, et al
    Continued value of the serum alpha-fetoprotein test in surveilling at-risk populations for hepatocellular carcinoma.
    PLoS One. 2020;15:e0238078.
    PubMed     Abstract available

  37. LEE J, Vali Y, Boursier J, Duffin K, et al
    Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0238717.
    PubMed     Abstract available

  38. HAYASHI M, Abe K, Fujita M, Takahashi A, et al
    Association between serum ficolin-1 level and disease progression in primary biliary cholangitis.
    PLoS One. 2020;15:e0238300.
    PubMed     Abstract available

  39. WALDENSTROM J, Nystrom K, Nilsson S, Norkrans G, et al
    The relation of 25-hydroxy vitamin D concentrations to liver histopathology, seasonality and baseline characteristics in chronic hepatitis C virus genotype 2 or 3 infection.
    PLoS One. 2020;15:e0237840.
    PubMed     Abstract available

  40. GRIFFETT K, Bedia-Diaz G, Elgendy B, Burris TP, et al
    REV-ERB agonism improves liver pathology in a mouse model of NASH.
    PLoS One. 2020;15:e0236000.
    PubMed     Abstract available

  41. PAPALUCA T, Craigie A, McDonald L, Edwards A, et al
    Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C.
    PLoS One. 2020;15:e0242101.
    PubMed     Abstract available

  42. SAKAMAKI A, Yokoyama K, Koyama K, Morita S, et al
    Obesity and accumulation of subcutaneous adipose tissue are poor prognostic factors in patients with alcoholic liver cirrhosis.
    PLoS One. 2020;15:e0242582.
    PubMed     Abstract available

  43. JIANG K, Mohammad MK, Dar WA, Kong J, et al
    Quantitative assessment of liver fibrosis by digital image analysis reveals correlation with qualitative clinical fibrosis staging in liver transplant patients.
    PLoS One. 2020;15:e0239624.
    PubMed     Abstract available

  44. ABE K, Wakabayashi H, Nakayama H, Suzuki T, et al
    Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis.
    PLoS One. 2020;15:e0243473.
    PubMed     Abstract available

  45. YEN FS, Lai JN, Wei JC, Chiu LT, et al
    Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis.
    PLoS One. 2020;15:e0243783.
    PubMed     Abstract available

  46. AMORAS EDSG, Monteiro Gomes ST, Freitas Queiroz MA, de Araujo MSM, et al
    Intrahepatic interleukin 10 expression modulates fibrinogenesis during chronic HCV infection.
    PLoS One. 2020;15:e0241199.
    PubMed     Abstract available

  47. KIM MC, Lee JI, Kim JH, Kim HJ, et al
    Serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease.
    PLoS One. 2020;15:e0240195.
    PubMed     Abstract available

  48. THOMSEN H, Li X, Sundquist K, Sundquist J, et al
    Familial associations between autoimmune hepatitis and primary biliary cholangitis and other autoimmune diseases.
    PLoS One. 2020;15:e0240794.
    PubMed     Abstract available

  49. FENG L, Dong K, Zhang X, Ma B, et al
    Clinical significance of IgG antimitochondrial M2 antibody levels in primary biliary cholangitis: A single center study from China.
    PLoS One. 2020;15:e0242164.
    PubMed     Abstract available

  50. LEE JJ, Wei YJ, Lin MY, Niu SW, et al
    The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C.
    PLoS One. 2020;15:e0242601.
    PubMed     Abstract available

  51. BRAUNWARTH E, Rumpf B, Primavesi F, Pereyra D, et al
    Sex differences in disease presentation, surgical and oncological outcome of liver resection for primary and metastatic liver tumors-A retrospective multicenter study.
    PLoS One. 2020;15:e0243539.
    PubMed     Abstract available

  52. BAYOUMI A, Jalil I, Metwally M, Adams LA, et al
    Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease.
    PLoS One. 2020;15:e0243590.
    PubMed     Abstract available

  53. SOHOLM J, Hansen JF, Mossner B, Roge BT, et al
    Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs.
    PLoS One. 2020;15:e0243725.
    PubMed     Abstract available

  54. YUAN Y, Naito H, Kitamori K, Hashimoto S, et al
    The antihypertensive agent hydralazine reduced extracellular matrix synthesis and liver fibrosis in nonalcoholic steatohepatitis exacerbated by hypertension.
    PLoS One. 2020;15:e0243846.
    PubMed     Abstract available

  55. SEMMLER G, Bachmayer S, Wernly S, Wernly B, et al
    Nut consumption and the prevalence and severity of non-alcoholic fatty liver disease.
    PLoS One. 2020;15:e0244514.
    PubMed     Abstract available

    January 2019
  56. REZAEI N, Asadi-Lari M, Sheidaei A, Khademi S, et al
    Liver cirrhosis mortality at national and provincial levels in Iran between 1990 and 2015: A meta regression analysis.
    PLoS One. 2019;14:e0198449.
    PubMed     Abstract available

  57. SCHWARZKOPF KM, Queck A, Thomas D, Angioni C, et al
    Omega-3 and -6 fatty acid plasma levels are not associated with liver cirrhosis-associated systemic inflammation.
    PLoS One. 2019;14:e0211537.
    PubMed     Abstract available

  58. TAKADA H, Kurosaki M, Nakanishi H, Takahashi Y, et al
    Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures.
    PLoS One. 2019;14:e0211122.
    PubMed     Abstract available

  59. MUKTHINUTHALAPATI VVPK, Akinyeye S, Fricker ZP, Syed M, et al
    Early predictors of outcomes of hospitalization for cirrhosis and assessment of the impact of race and ethnicity at safety-net hospitals.
    PLoS One. 2019;14:e0211811.
    PubMed     Abstract available

  60. HUANG CH, Wu LS, Jeng WJ, Cheng YF, et al
    In HCV-related liver cirrhosis, local pulse wave velocity increases and in decompensated patients correlates with poorer survival.
    PLoS One. 2019;14:e0212770.
    PubMed     Abstract available

  61. DU Z, Dong J, Bi J, Bai R, et al
    Correction: Predictive value of the preoperative neutrophil-to-lymphocyte ratio for the development of hepatocellular carcinoma in HBV-associated cirrhotic patients after splenectomy.
    PLoS One. 2019;14:e0215183.
    PubMed     Abstract available

  62. HUNG TH, Tseng CW, Tsai CC, Lee HF, et al
    Effect of proton pump inhibitors on mortality of cirrhotic patients with pneumonia.
    PLoS One. 2019;14:e0216041.
    PubMed     Abstract available

  63. HUNG TH, Tsai CC, Lee HF
    Statin use in cirrhotic patients with infectious diseases: A population-based study.
    PLoS One. 2019;14:e0215839.
    PubMed     Abstract available

  64. RIBERA J, Rodriguez-Vita J, Cordoba B, Portoles I, et al
    Functionalized cerium oxide nanoparticles mitigate the oxidative stress and pro-inflammatory activity associated to the portal vein endothelium of cirrhotic rats.
    PLoS One. 2019;14:e0218716.
    PubMed     Abstract available

  65. KIMMANN M, Tergast TL, Schultalbers M, Laser H, et al
    Sustained impact of nosocomial-acquired spontaneous bacterial peritonitis in different stages of decompensated liver cirrhosis.
    PLoS One. 2019;14:e0220666.
    PubMed     Abstract available

  66. Retraction: The Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection and Cirrhosis.
    PLoS One. 2019;14:e0222176.

  67. GARNAES E, Mortensen C, Hobolth L, Andersen O, et al
    Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis.
    PLoS One. 2019;14:e0220697.
    PubMed     Abstract available

  68. UYEI J, Taddei TH, Kaplan DE, Chapko M, et al
    Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study.
    PLoS One. 2019;14:e0221614.
    PubMed     Abstract available

  69. NAVARRO VJ, Belle SH, D'Amato M, Adfhal N, et al
    Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial.
    PLoS One. 2019;14:e0221683.
    PubMed     Abstract available

  70. SENKERIKOVA R, Frankova S, Jirsa M, Kreidlova M, et al
    PNPLA3 rs738409 G allele carriers with genotype 1b HCV cirrhosis have lower viral load but develop liver failure at younger age.
    PLoS One. 2019;14:e0222609.
    PubMed     Abstract available

  71. YEN YH, Kee KM, Chen CH, Hu TH, et al
    Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C.
    PLoS One. 2019;14:e0208858.
    PubMed     Abstract available

  72. NORONA LM, Nguyen DG, Gerber DA, Presnell SC, et al
    Bioprinted liver provides early insight into the role of Kupffer cells in TGF-beta1 and methotrexate-induced fibrogenesis.
    PLoS One. 2019;14:e0208958.
    PubMed     Abstract available

  73. WU VC, Chen SW, Chou AH, Ting PC, et al
    Dual antiplatelet therapy in patients with cirrhosis and acute myocardial infarction - A 13-year nationwide cohort study.
    PLoS One. 2019;14:e0223380.
    PubMed     Abstract available

  74. BERNI ER, Jones BI, Berni TR, Whitehouse J, et al
    The Model of Mortality with Incident Cirrhosis (MoMIC) and the model of Long-term Outlook of Mortality in Cirrhosis (LOMiC).
    PLoS One. 2019;14:e0223253.
    PubMed     Abstract available

  75. OUD L
    In-hospital cardiopulmonary resuscitation of patients with cirrhosis: A population-based analysis.
    PLoS One. 2019;14:e0222873.
    PubMed     Abstract available

  76. BAJAJ JS, Fan S, Thacker LR, Fagan A, et al
    Serum and urinary metabolomics and outcomes in cirrhosis.
    PLoS One. 2019;14:e0223061.
    PubMed     Abstract available

  77. NAVARRO VJ, Belle SH, D'Amato M, Afdhal N, et al
    Correction: Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial.
    PLoS One. 2019;14:e0223915.
    PubMed     Abstract available

  78. KAYS JK, Milgrom DP, Butler JR, Liang TW, et al
    Specialized care improves outcomes for patients with cirrhosis who require general surgical operations.
    PLoS One. 2019;14:e0223454.
    PubMed     Abstract available

  79. NISHIMURA T, Takami T, Sasaki R, Aibe Y, et al
    Liver regeneration therapy through the hepatic artery-infusion of cultured bone marrow cells in a canine liver fibrosis model.
    PLoS One. 2019;14:e0210588.
    PubMed     Abstract available

  80. FANTILLI AC, Trinks J, Marciano S, Zarate F, et al
    Unexpected high seroprevalence of hepatitis E virus in patients with alcohol-related cirrhosis.
    PLoS One. 2019;14:e0224404.
    PubMed     Abstract available

  81. QUECK A, Thomas D, Jansen C, Schreiber Y, et al
    Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis.
    PLoS One. 2019;14:e0222840.
    PubMed     Abstract available

  82. WANG Y, Cobanoglu MC, Li J, Hidvegi T, et al
    An analog of glibenclamide selectively enhances autophagic degradation of misfolded alpha1-antitrypsin Z.
    PLoS One. 2019;14:e0209748.
    PubMed     Abstract available

  83. HANSEN JF, Christiansen KM, Staugaard B, Moessner BK, et al
    Combining liver stiffness with hyaluronic acid provides superior prognostic performance in chronic hepatitis C.
    PLoS One. 2019;14:e0212036.
    PubMed     Abstract available

  84. SHENGE JA, Odaibo GN, Olaleye DO
    Phylogenetic analysis of hepatitis C virus among HIV/ HCV co-infected patients in Nigeria.
    PLoS One. 2019;14:e0210724.
    PubMed     Abstract available

  85. SKOGLUND C, Lagging M, Castedal M
    No need to discontinue hepatitis C virus therapy at the time of liver transplantation.
    PLoS One. 2019;14:e0211437.
    PubMed     Abstract available

  86. YAMADA S, Shimada M, Morine Y, Imura S, et al
    A new formula to calculate the resection limit in hepatectomy based on Gd-EOB-DTPA-enhanced magnetic resonance imaging.
    PLoS One. 2019;14:e0210579.
    PubMed     Abstract available

  87. HO CH, Chang TT, Chien RN
    Telbivudine on IgG-associated hypergammaglobulinemia and TGF-beta1 hyperactivity in hepatitis B virus-related liver cirrhosis.
    PLoS One. 2019;14:e0225482.
    PubMed     Abstract available

  88. PARK DW, Lee YJ, Chang W, Park JH, et al
    Diagnostic performance of a point shear wave elastography (pSWE) for hepatic fibrosis in patients with autoimmune liver disease.
    PLoS One. 2019;14:e0212771.
    PubMed     Abstract available

  89. MOSHER V, Swain M, Pang J, Kaplan G, et al
    Primary biliary cholangitis patients exhibit MRI changes in structure and function of interoceptive brain regions.
    PLoS One. 2019;14:e0211906.
    PubMed     Abstract available

  90. WERNBERG CW, Schaffalitzky de Muckadell OB, Vilstrup H, M Lauridsen M, et al
    Prediction of overt hepatic encephalopathy by the continuous reaction time method and the portosystemic encephalopathy syndrome test in clinically mentally unimpaired patients with cirrhosis.
    PLoS One. 2019;14:e0226283.
    PubMed     Abstract available

  91. TOLEDANO MB, Mukherjee SK, Howell J, Westaby D, et al
    The emerging burden of liver disease in cystic fibrosis patients: A UK nationwide study.
    PLoS One. 2019;14:e0212779.
    PubMed     Abstract available

  92. LEE YC, Hu TH, Hung CH, Lu SN, et al
    The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals.
    PLoS One. 2019;14:e0214323.
    PubMed     Abstract available

  93. MANGIA A, Piazzolla V, Giannelli A, Visaggi E, et al
    SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
    PLoS One. 2019;14:e0215783.
    PubMed     Abstract available

  94. VERLOH N, Probst U, Utpatel K, Zeman F, et al
    Influence of hepatic fibrosis and inflammation: Correlation between histopathological changes and Gd-EOB-DTPA-enhanced MR imaging.
    PLoS One. 2019;14:e0215752.
    PubMed     Abstract available

  95. GUPTA P, Sata TN, Yadav AK, Mishra A, et al
    TGF-beta induces liver fibrosis via miRNA-181a-mediated down regulation of augmenter of liver regeneration in hepatic stellate cells.
    PLoS One. 2019;14:e0214534.
    PubMed     Abstract available

  96. CHENG YW, Chang YC, Chen YL, Chen RC, et al
    Feasibility of measuring spleen stiffness with MR elastography and splenic volume to predict hepatic fibrosis stage.
    PLoS One. 2019;14:e0217876.
    PubMed     Abstract available

  97. CARBONELL G, Berna-Serna JD, Oltra L, Martinez CM, et al
    Evaluation of rat liver with ARFI elastography: In vivo and ex vivo study.
    PLoS One. 2019;14:e0217297.
    PubMed     Abstract available

  98. EL AWDAN SA, Abdel Rahman RF, Ibrahim HM, Hegazy RR, et al
    Regression of fibrosis by cilostazol in a rat model of thioacetamide-induced liver fibrosis: Up regulation of hepatic cAMP, and modulation of inflammatory, oxidative stress and apoptotic biomarkers.
    PLoS One. 2019;14:e0216301.
    PubMed     Abstract available

  99. BAROCAS JA, So-Armah K, Cheng DM, Lioznov D, et al
    Zinc deficiency and advanced liver fibrosis among HIV and hepatitis C co-infected anti-retroviral naive persons with alcohol use in Russia.
    PLoS One. 2019;14:e0218852.
    PubMed     Abstract available

  100. PARK J, Lee J, Kwon A, Choi HJ, et al
    The 2016 ASE/EACVI recommendations may be able to more accurately identify patients at risk for diastolic dysfunction in living donor liver transplantation.
    PLoS One. 2019;14:e0215603.
    PubMed     Abstract available

  101. YEE C, Main NM, Terry A, Stevanovski I, et al
    CD147 mediates intrahepatic leukocyte aggregation and determines the extent of liver injury.
    PLoS One. 2019;14:e0215557.
    PubMed     Abstract available

  102. KAR S, Paglialunga S, Jaycox SH, Islam R, et al
    Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosis.
    PLoS One. 2019;14:e0217263.
    PubMed     Abstract available

  103. PEDROZA M, To S, Smith J, Agarwal SK, et al
    Cadherin-11 contributes to liver fibrosis induced by carbon tetrachloride.
    PLoS One. 2019;14:e0218971.
    PubMed     Abstract available

  104. RAIHAN R, Akbar SMF, Al Mahtab M, Takahashi K, et al
    Genomic analysis of Hepatitis B virus and its association with disease manifestations in Bangladesh.
    PLoS One. 2019;14:e0218744.
    PubMed     Abstract available

  105. PENG CH, Lee HC, Jiang CB, Hsu CK, et al
    Serum vitamin D level is inversely associated with liver fibrosis in post Kasai's portoenterostomy biliary atresia patients living with native liver.
    PLoS One. 2019;14:e0218896.
    PubMed     Abstract available

  106. BREZZI M, Bertisch B, Roelens M, Moradpour D, et al
    Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study.
    PLoS One. 2019;14:e0218706.
    PubMed     Abstract available

  107. DOLD L, Nielsen MJ, Praktiknjo M, Schwarze-Zander C, et al
    Circulating levels of PRO-C3 reflect liver fibrosis and liver function in HIV positive patients receiving modern cART.
    PLoS One. 2019;14:e0219526.
    PubMed     Abstract available

  108. MAIPANG K, Potranun P, Chainuvati S, Nimanong S, et al
    Validation of the prognostic models in acute-on-chronic liver failure precipitated by hepatic and extrahepatic insults.
    PLoS One. 2019;14:e0219516.
    PubMed     Abstract available

  109. PENG W, Li JW, Zhang XY, Li C, et al
    A novel model for predicting posthepatectomy liver failure in patients with hepatocellular carcinoma.
    PLoS One. 2019;14:e0219219.
    PubMed     Abstract available

  110. WAGNER J, Fillebeen C, Haliotis T, Charlebois E, et al
    Mouse models of hereditary hemochromatosis do not develop early liver fibrosis in response to a high fat diet.
    PLoS One. 2019;14:e0221455.
    PubMed     Abstract available

  111. PARK MR, Wong MS, Arauzo-Bravo MJ, Lee H, et al
    Oct4 and Hnf4alpha-induced hepatic stem cells ameliorate chronic liver injury in liver fibrosis model.
    PLoS One. 2019;14:e0221085.
    PubMed     Abstract available

  112. BASKIC D, Vukovic V, Popovic S, Jovanovic D, et al
    Chronic Hepatitis C: Conspectus of immunological events in the course of fibrosis evolution.
    PLoS One. 2019;14:e0219508.
    PubMed     Abstract available

  113. HUANG YJ, Yang SS, Yeh HZ, Chang CS, et al
    Association of virological breakthrough and clinical outcomes in entecavir-treated HBeAg-positive chronic hepatitis B.
    PLoS One. 2019;14:e0221958.
    PubMed     Abstract available

  114. WONG RJ, Tran T, Kaufman H, Niles J, et al
    Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis.
    PLoS One. 2019;14:e0220612.
    PubMed     Abstract available

  115. GERHARD GS, Hanson A, Wilhelmsen D, Piras IS, et al
    AEBP1 expression increases with severity of fibrosis in NASH and is regulated by glucose, palmitate, and miR-372-3p.
    PLoS One. 2019;14:e0219764.
    PubMed     Abstract available

  116. SEMMLER G, Scheiner B, Schwabl P, Bucsics T, et al
    The impact of hepatic steatosis on portal hypertension.
    PLoS One. 2019;14:e0224506.
    PubMed     Abstract available

  117. GARDINI I, Bartoli M, Conforti M, Mennini FS, et al
    Estimation of the number of HCV-positive patients in Italy.
    PLoS One. 2019;14:e0223668.
    PubMed     Abstract available

  118. FOLADOR L, Torres FS, Zampieri JF, Machado BC, et al
    Hepatopulmonary syndrome has low prevalence of pulmonary vascular abnormalities on chest computed tomography.
    PLoS One. 2019;14:e0223805.
    PubMed     Abstract available

  119. YEH ML, Huang CF, Huang CI, Dai CY, et al
    Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients.
    PLoS One. 2019;14:e0220663.
    PubMed     Abstract available

  120. SUDJARITRUK T, Bunupuradah T, Aurpibul L, Kosalaraksa P, et al
    Nonalcoholic fatty liver disease and hepatic fibrosis among perinatally HIV-monoinfected Asian adolescents receiving antiretroviral therapy.
    PLoS One. 2019;14:e0226375.
    PubMed     Abstract available

  121. ISHIKAWA T, Sasaki R, Nishimura T, Aibe Y, et al
    A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification.
    PLoS One. 2019;14:e0223153.
    PubMed     Abstract available

  122. LEVICK C, Phillips-Hughes J, Collier J, Banerjee R, et al
    Non-invasive assessment of portal hypertension by multi-parametric magnetic resonance imaging of the spleen: A proof of concept study.
    PLoS One. 2019;14:e0221066.
    PubMed     Abstract available

    January 2018
  123. LIU TL, Barritt AS Th, Weinberger M, Paul JE, et al
    Correction: Who Treats Patients with Diabetes and Compensated Cirrhosis.
    PLoS One. 2018;13:e0190756.
    PubMed     Abstract available

  124. ANADOL E, Lust K, Boesecke C, Schwarze-Zander C, et al
    Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients.
    PLoS One. 2018;13:e0191118.
    PubMed     Abstract available

  125. BUCSICS T, Schoder M, Diermayr M, Feldner-Busztin M, et al
    Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding - A two decades experience.
    PLoS One. 2018;13:e0189414.
    PubMed     Abstract available

  126. SARACINO A, Cozzi-Lepri A, Shanyinde M, Ceccherini Silberstein F, et al
    HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients.
    PLoS One. 2018;13:e0190302.
    PubMed     Abstract available

  127. RAUBER P, Lammert F, Grotemeyer K, Appenrodt B, et al
    Immature platelet fraction and thrombopoietin in patients with liver cirrhosis: A cohort study.
    PLoS One. 2018;13:e0192271.
    PubMed     Abstract available

  128. KELLY ML, Riordan SM, Bopage R, Lloyd AR, et al
    Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study.
    PLoS One. 2018;13:e0192763.
    PubMed     Abstract available

  129. MULABECIROVIC A, Mjelle AB, Gilja OH, Vesterhus M, et al
    Repeatability of shear wave elastography in liver fibrosis phantoms-Evaluation of five different systems.
    PLoS One. 2018;13:e0189671.
    PubMed     Abstract available

  130. YAMADA K, Mizukoshi E, Seike T, Horii R, et al
    Light alcohol consumption has the potential to suppress hepatocellular injury and liver fibrosis in non-alcoholic fatty liver disease.
    PLoS One. 2018;13:e0191026.
    PubMed     Abstract available

  131. LIAO CY, Chung CH, Chu P, Wei KY, et al
    Increased risk of osteoporosis in patients with primary biliary cirrhosis.
    PLoS One. 2018;13:e0194418.
    PubMed     Abstract available

  132. DI POTO C, He S, Varghese RS, Zhao Y, et al
    Identification of race-associated metabolite biomarkers for hepatocellular carcinoma in patients with liver cirrhosis and hepatitis C virus infection.
    PLoS One. 2018;13:e0192748.
    PubMed     Abstract available

  133. LE CT, Nguyen G, Park SY, Choi DH, et al
    LY2405319, an analog of fibroblast growth factor 21 ameliorates alpha-smooth muscle actin production through inhibition of the succinate-G-protein couple receptor 91 (GPR91) pathway in mice.
    PLoS One. 2018;13:e0192146.
    PubMed     Abstract available

  134. DU Z, Dong J, Bi J, Bai R, et al
    Predictive value of the preoperative neutrophil-to-lymphocyte ratio for the development of hepatocellular carcinoma in HBV-associated cirrhotic patients after splenectomy.
    PLoS One. 2018;13:e0195336.
    PubMed     Abstract available

  135. JANSEN C, Al-Kassou B, Lehmann J, Pohlmann A, et al
    Severe abnormal Heart Rate Turbulence Onset is associated with deterioration of liver cirrhosis.
    PLoS One. 2018;13:e0195631.
    PubMed     Abstract available

  136. HEMMINGER J, Arole V, Ayoub I, Brodsky SV, et al
    Acute glomerulonephritis with large confluent IgA-dominant deposits associated with liver cirrhosis.
    PLoS One. 2018;13:e0193274.
    PubMed     Abstract available

  137. YETTI H, Naito H, Yuan Y, Jia X, et al
    Bile acid detoxifying enzymes limit susceptibility to liver fibrosis in female SHRSP5/Dmcr rats fed with a high-fat-cholesterol diet.
    PLoS One. 2018;13:e0192863.
    PubMed     Abstract available

  138. YUAN LT, Chuah SK, Yang SC, Liang CM, et al
    Multiple bacterial infections increase the risk of hepatic encephalopathy in patients with cirrhosis.
    PLoS One. 2018;13:e0197127.
    PubMed     Abstract available

  139. KROHN S, Zeller K, Bohm S, Chatzinotas A, et al
    Molecular quantification and differentiation of Candida species in biological specimens of patients with liver cirrhosis.
    PLoS One. 2018;13:e0197319.
    PubMed     Abstract available

  140. NGUYEN HH, Shaheen AA, Baeza N, Lytvyak E, et al
    Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS).
    PLoS One. 2018;13:e0193960.
    PubMed     Abstract available

  141. MAYR U, Karsten E, Lahmer T, Rasch S, et al
    Impact of large volume paracentesis on respiratory parameters including transpulmonary pressure and on transpulmonary thermodilution derived hemodynamics: A prospective study.
    PLoS One. 2018;13:e0193654.
    PubMed     Abstract available

  142. MAUNOURY F, Clement A, Nwankwo C, Levy-Bachelot L, et al
    Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
    PLoS One. 2018;13:e0194329.
    PubMed     Abstract available

  143. MIOTTO N, Mendes LC, Zanaga LP, Lazarini MSK, et al
    All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response.
    PLoS One. 2018;13:e0199941.
    PubMed     Abstract available

  144. SHAHEEN AA, Kaplan GG, Almishri W, Vallerand I, et al
    The impact of depression and antidepressant usage on primary biliary cholangitis clinical outcomes.
    PLoS One. 2018;13:e0194839.
    PubMed     Abstract available

  145. BIAN S, Chen H, Wang L, Fei Y, et al
    Cardiac involvement in patients with primary biliary cholangitis: A 14-year longitudinal survey-based study.
    PLoS One. 2018;13:e0194397.
    PubMed     Abstract available

  146. KELLER S, Aigner A, Zenouzi R, Kim AC, et al
    Association of gadolinium-enhanced magnetic resonance imaging with hepatic fibrosis and inflammation in primary sclerosing cholangitis.
    PLoS One. 2018;13:e0193929.
    PubMed     Abstract available

  147. SATSANGI S, Duseja A, Sachdeva M, Tomer S, et al
    Monocyte human leukocyte antigen - Antigen D related, neutrophil oxidative burst and cytokine analysis in patients of decompensated cirrhosis with and without acute-on chronic liver failure.
    PLoS One. 2018;13:e0200644.
    PubMed     Abstract available

  148. FINKELMEIER F, Canli O, Peiffer KH, Walter D, et al
    Circulating hypoxia marker carbonic anhydrase IX (CA9) in patients with hepatocellular carcinoma and patients with cirrhosis.
    PLoS One. 2018;13:e0200855.
    PubMed     Abstract available

  149. GOLIZEH M, Melendez-Pena CE, Ward BJ, Saeed S, et al
    Proteomic fingerprinting in HIV/HCV co-infection reveals serum biomarkers for the diagnosis of fibrosis staging.
    PLoS One. 2018;13:e0195148.
    PubMed     Abstract available

  150. FRIEDMAN A, Siewe N
    Chronic hepatitis B virus and liver fibrosis: A mathematical model.
    PLoS One. 2018;13:e0195037.
    PubMed     Abstract available

  151. MANGIA A, Losappio R, Cenderello G, Potenza D, et al
    Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.
    PLoS One. 2018;13:e0200568.
    PubMed     Abstract available

  152. ONICIU DC, Hashiguchi T, Shibazaki Y, Bisgaier CL, et al
    Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM model of NASH.
    PLoS One. 2018;13:e0194568.
    PubMed     Abstract available

  153. AXLEY P, Mudumbi S, Sarker S, Kuo YF, et al
    Patients with stage 3 compared to stage 4 liver fibrosis have lower frequency of and longer time to liver disease complications.
    PLoS One. 2018;13:e0197117.
    PubMed     Abstract available

  154. YAMAZAKI T, Joshita S, Umemura T, Usami Y, et al
    Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C.
    PLoS One. 2018;13:e0195632.
    PubMed     Abstract available

  155. EYRAUD D, Suner L, Dupont A, Bachelot-Loza C, et al
    Evolution of platelet functions in cirrhotic patients undergoing liver transplantation: A prospective exploration over a month.
    PLoS One. 2018;13:e0200364.
    PubMed     Abstract available

  156. JIMENEZ-SOUSA MA, Gomez-Moreno AZ, Pineda-Tenor D, Medrano LM, et al
    The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design.
    PLoS One. 2018;13:e0197115.
    PubMed     Abstract available

  157. REITER R, Wetzel M, Hamesch K, Strnad P, et al
    Comparison of non-invasive assessment of liver fibrosis in patients with alpha1-antitrypsin deficiency using magnetic resonance elastography (MRE), acoustic radiation force impulse (ARFI) Quantification, and 2D-shear wave elastography (2D-SWE).
    PLoS One. 2018;13:e0196486.
    PubMed     Abstract available

  158. PEISELER M, Reiners D, Pinnschmidt HO, Sebode M, et al
    Risk of endoscopic biliary interventions in primary sclerosing cholangitis is similar between patients with and without cirrhosis.
    PLoS One. 2018;13:e0202686.
    PubMed     Abstract available

  159. HSIEH YC, Jeng WJ, Huang CH, Teng W, et al
    Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.
    PLoS One. 2018;13:e0202777.
    PubMed     Abstract available

  160. LAPOINTE-SHAW L, Georgie F, Carlone D, Cerocchi O, et al
    Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study.
    PLoS One. 2018;13:e0201120.
    PubMed     Abstract available

  161. ALKHOURI N, Johnson C, Adams L, Kitajima S, et al
    Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
    PLoS One. 2018;13:e0202226.
    PubMed     Abstract available

  162. KIMER N, Gudmann NS, Pedersen JS, Moller S, et al
    No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial.
    PLoS One. 2018;13:e0203200.
    PubMed     Abstract available

  163. IOANNOU GN, Green P, Lowy E, Mun EJ, et al
    Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis.
    PLoS One. 2018;13:e0204412.
    PubMed     Abstract available

  164. ALKHOURI N, Johnson C, Adams L, Kitajima S, et al
    Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
    PLoS One. 2018;13:e0205541.
    PubMed     Abstract available

  165. KUBESCH A, Quenstedt L, Saleh M, Ruschenbaum S, et al
    Vitamin D deficiency is associated with hepatic decompensation and inflammation in patients with liver cirrhosis: A prospective cohort study.
    PLoS One. 2018;13:e0207162.
    PubMed     Abstract available

  166. KHAN B, Duncan I, Saad M, Schaefer D, et al
    Combination interventions for Hepatitis C and Cirrhosis reduction among people who inject drugs: An agent-based, networked population simulation experiment.
    PLoS One. 2018;13:e0206356.
    PubMed     Abstract available

  167. HSIEH YC, Lee KC, Wang YW, Yang YY, et al
    Correlation and prognostic accuracy between noninvasive liver fibrosismarkers and portal pressure in cirrhosis: Role of ALBI score.
    PLoS One. 2018;13:e0208903.
    PubMed     Abstract available

  168. GROTTENTHALER JM, Werner CR, Steurer M, Spengler U, et al
    Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
    PLoS One. 2018;13:e0197544.
    PubMed     Abstract available

  169. WANG HW, Shi HN, Cheng J, Xie F, et al
    Real-time shear wave elastography (SWE) assessment of short- and long-term treatment outcome in Budd-Chiari syndrome: A pilot study.
    PLoS One. 2018;13:e0197550.
    PubMed     Abstract available

  170. YEN YH, Kuo FY, Kee KM, Chang KC, et al
    APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level.
    PLoS One. 2018;13:e0199760.
    PubMed     Abstract available

  171. ABE K, Takahashi A, Fujita M, Imaizumi H, et al
    Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease.
    PLoS One. 2018;13:e0198757.
    PubMed     Abstract available

  172. CHANG PE, Goh GBB, Leow WQ, Shen L, et al
    Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease.
    PLoS One. 2018;13:e0199166.
    PubMed     Abstract available

  173. OBMANN VC, Mertineit N, Berzigotti A, Marx C, et al
    CT predicts liver fibrosis: Prospective evaluation of morphology- and attenuation-based quantitative scores in routine portal venous abdominal scans.
    PLoS One. 2018;13:e0199611.
    PubMed     Abstract available

  174. EVON DM, Stewart PW, Amador J, Serper M, et al
    A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study.
    PLoS One. 2018;13:e0196908.
    PubMed     Abstract available

  175. KIM SE, Park JW, Kim MJ, Jang B, et al
    Accumulation of citrullinated glial fibrillary acidic protein in a mouse model of bile duct ligation-induced hepatic fibrosis.
    PLoS One. 2018;13:e0201744.
    PubMed     Abstract available

  176. SCHAEFER B, Viveiros A, Al-Zoairy R, Blach S, et al
    Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030.
    PLoS One. 2018;13:e0200750.
    PubMed     Abstract available

  177. PELEG N, Sneh Arbib O, Issachar A, Cohen-Naftaly M, et al
    Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease.
    PLoS One. 2018;13:e0202393.
    PubMed     Abstract available

  178. ALISI A, Pampanini V, De Stefanis C, Panera N, et al
    Expression of insulin-like growth factor I and its receptor in the liver of children with biopsy-proven NAFLD.
    PLoS One. 2018;13:e0201566.
    PubMed     Abstract available

  179. KRUK B, Liebe R, Milkiewicz M, Wunsch E, et al
    PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.
    PLoS One. 2018;13:e0202942.
    PubMed     Abstract available

  180. HARRISON SA, Dennis A, Fiore MM, Kelly MD, et al
    Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial.
    PLoS One. 2018;13:e0203054.
    PubMed     Abstract available

  181. FRANSEN PETTERSSON N, Deronic A, Nilsson J, Hannibal TD, et al
    The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis.
    PLoS One. 2018;13:e0203228.
    PubMed     Abstract available

  182. XING YF, Zhou DQ, He JS, Wei CS, et al
    Clinical and histopathological features of chronic hepatitis B virus infected patients with high HBV-DNA viral load and normal alanine aminotransferase level: A multicentre-based study in China.
    PLoS One. 2018;13:e0203220.
    PubMed     Abstract available

  183. DILLARD KJ, Hytonen MK, Fischer D, Tanhuanpaa K, et al
    A splice site variant in INPP5E causes diffuse cystic renal dysplasia and hepatic fibrosis in dogs.
    PLoS One. 2018;13:e0204073.
    PubMed     Abstract available

  184. ROMUALDO GR, Prata GB, da Silva TC, Fernandes AAH, et al
    Fibrosis-associated hepatocarcinogenesis revisited: Establishing standard medium-term chemically-induced male and female models.
    PLoS One. 2018;13:e0203879.
    PubMed     Abstract available

  185. TAKAHASHI A, Moriya K, Ohira H, Arinaga-Hino T, et al
    Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey.
    PLoS One. 2018;13:e0204772.
    PubMed     Abstract available

  186. MCCLURE MW, Berliba E, Tsertsvadze T, Streinu-Cercel A, et al
    Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects.
    PLoS One. 2018;13:e0204974.
    PubMed     Abstract available

  187. POLINENI D, Piccorelli AV, Hannah WB, Dalrymple SN, et al
    Analysis of a large cohort of cystic fibrosis patients with severe liver disease indicates lung function decline does not significantly differ from that of the general cystic fibrosis population.
    PLoS One. 2018;13:e0205257.
    PubMed     Abstract available

  188. ALMEER RS, El-Khadragy MF, Abdelhabib S, Abdel Moneim AE, et al
    Ziziphus spina-christi leaf extract ameliorates schistosomiasis liver granuloma, fibrosis, and oxidative stress through downregulation of fibrinogenic signaling in mice.
    PLoS One. 2018;13:e0204923.
    PubMed     Abstract available

  189. LEE SH, Park M, Park KM, Gwag HB, et al
    Corrected QT interval on the electrocardiogram after liver transplantation: Surrogate marker of poor clinical outcomes?
    PLoS One. 2018;13:e0206463.
    PubMed     Abstract available

  190. FAROUK S, Sabet S, Abu Zahra FA, El-Ghor AA, et al
    Bone marrow derived-mesenchymal stem cells downregulate IL17A dependent IL6/STAT3 signaling pathway in CCl4-induced rat liver fibrosis.
    PLoS One. 2018;13:e0206130.
    PubMed     Abstract available

  191. LIU C, Wang L, Xie H, Zhang L, et al
    The relationship between serum hepatitis B virus DNA level and liver histology in patients with chronic HBV infection.
    PLoS One. 2018;13:e0206060.
    PubMed     Abstract available

  192. UCHIDA Y, Naiki K, Kouyama JI, Sugawara K, et al
    Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
    PLoS One. 2018;13:e0205600.
    PubMed     Abstract available

  193. DAHER S, Lev Cohen N, Massarwa M, Mahamid M, et al
    Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease.
    PLoS One. 2018;13:e0207479.
    PubMed     Abstract available

  194. CHENG PN, Chiu HC, Chiu YC, Chen SC, et al
    Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community.
    PLoS One. 2018;13:e0206947.
    PubMed     Abstract available

  195. BILLA O, Chalouni M, Salmon D, Poizot-Martin I, et al
    Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort.
    PLoS One. 2018;13:e0208657.
    PubMed     Abstract available

  196. MULLHAUPT B, Bruggmann P, Bihl F, Blach S, et al
    Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
    PLoS One. 2018;13:e0209374.
    PubMed     Abstract available

  197. PAPIC N, Zidovec Lepej S, Gorenec L, Grgic I, et al
    The association of semaphorins 3C, 5A and 6D with liver fibrosis stage in chronic hepatitis C.
    PLoS One. 2018;13:e0209481.
    PubMed     Abstract available

    January 2017
  198. YANG SC, Hsu CN, Liang CM, Tai WC, et al
    Risk of Rebleeding and Mortality in Cirrhotic Patients with Peptic Ulcer Bleeding: A 12-Year Nationwide Cohort Study.
    PLoS One. 2017;12:e0168918.
    PubMed     Abstract available

  199. DEGRE D, Serste T, Lasser L, Delwaide J, et al
    Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.
    PLoS One. 2017;12:e0170933.
    PubMed     Abstract available

  200. GIMENEZ-GARZO C, Garces JJ, Urios A, Mangas-Losada A, et al
    The PHES battery does not detect all cirrhotic patients with early neurological deficits, which are different in different patients.
    PLoS One. 2017;12:e0171211.
    PubMed     Abstract available

  201. TRAYKOVA D, Schneider B, Chojkier M, Buck M, et al
    Blood Microbiome Quantity and the Hyperdynamic Circulation in Decompensated Cirrhotic Patients.
    PLoS One. 2017;12:e0169310.
    PubMed     Abstract available

  202. HOLLENBACH M, Thonig A, Pohl S, Ripoll C, et al
    Expression of glyoxalase-I is reduced in cirrhotic livers: A possible mechanism in the development of cirrhosis.
    PLoS One. 2017;12:e0171260.
    PubMed     Abstract available

  203. BECKER S, Kinny-Koster B, Bartels M, Scholz M, et al
    Low sphingosine-1-phosphate plasma levels are predictive for increased mortality in patients with liver cirrhosis.
    PLoS One. 2017;12:e0174424.
    PubMed     Abstract available

  204. WANG YC, Chou CT, Lin CP, Chen YL, et al
    The value of Gd-EOB-DTPA-enhanced MR imaging in characterizing cirrhotic nodules with atypical enhancement on Gd-DTPA-enhanced MR images.
    PLoS One. 2017;12:e0174594.
    PubMed     Abstract available

  205. GAO B, Zhang X, Huang Y, Yang Z, et al
    Coding and non-coding gene regulatory networks underlie the immune response in liver cirrhosis.
    PLoS One. 2017;12:e0174142.
    PubMed     Abstract available

  206. YE Q, Yin W, Zhang L, Xiao H, et al
    The value of grip test, lysophosphatidlycholines, glycerophosphocholine, ornithine, glucuronic acid decrement in assessment of nutritional and metabolic characteristics in hepatitis B cirrhosis.
    PLoS One. 2017;12:e0175165.
    PubMed     Abstract available

  207. IBUSUKI R, Uto H, Oda K, Ohshige A, et al
    Human neutrophil peptide-1 promotes alcohol-induced hepatic fibrosis and hepatocyte apoptosis.
    PLoS One. 2017;12:e0174913.
    PubMed     Abstract available

  208. KREMERS RMW, Kleinegris MC, Ninivaggi M, de Laat B, et al
    Decreased prothrombin conversion and reduced thrombin inactivation explain rebalanced thrombin generation in liver cirrhosis.
    PLoS One. 2017;12:e0177020.
    PubMed     Abstract available

  209. YOON K, Jeong WK, Kim Y, Kim MY, et al
    2-dimensional shear wave elastography: Interobserver agreement and factors related to interobserver discrepancy.
    PLoS One. 2017;12:e0175747.
    PubMed     Abstract available

  210. MCPHERSON S, Wilkinson N, Tiniakos D, Wilkinson J, et al
    A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.
    PLoS One. 2017;12:e0175717.
    PubMed     Abstract available

  211. LI Z, Lin B, Lin G, Wu Y, et al
    Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis.
    PLoS One. 2017;12:e0178580.
    PubMed     Abstract available

  212. CHIU NC, Su CW, Liu CA, Huang YH, et al
    Interval to vascularization development in cirrhotic precursor nodules in patients with hepatitis B and C virus co-infections.
    PLoS One. 2017;12:e0178841.
    PubMed     Abstract available

  213. HAN EC, Ryoo SB, Park JW, Yi JW, et al
    Oncologic and surgical outcomes in colorectal cancer patients with liver cirrhosis: A propensity-matched study.
    PLoS One. 2017;12:e0178920.
    PubMed     Abstract available

  214. CHANG CC, Lee WS, Hsieh HG, Chuang CL, et al
    Selective cyclooxygenase inhibition by SC-560 improves hepatopulmonary syndrome in cirrhotic rats.
    PLoS One. 2017;12:e0179809.
    PubMed     Abstract available

  215. HUNG TH, Liang CM, Hsu CN, Tai WC, et al
    Association between complicated liver cirrhosis and the risk of hepatocellular carcinoma in Taiwan.
    PLoS One. 2017;12:e0181858.
    PubMed     Abstract available

  216. WU CK, Liang CM, Hsu CN, Hung TH, et al
    The Role of Adjuvant Acid Suppression on the Outcomes of Bleeding Esophageal Varices after Endoscopic Variceal Ligation.
    PLoS One. 2017;12:e0169884.
    PubMed     Abstract available

  217. ZHAO J, Zhai F, Cheng J, He Q, et al
    Evaluating the Significance of Viscoelasticity in Diagnosing Early-Stage Liver Fibrosis with Transient Elastography.
    PLoS One. 2017;12:e0170073.
    PubMed     Abstract available

  218. DONAIRES FS, Scatena NF, Alves-Paiva RM, Podlevsky JD, et al
    Telomere biology and telomerase mutations in cirrhotic patients with hepatocellular carcinoma.
    PLoS One. 2017;12:e0183287.
    PubMed     Abstract available

  219. LIU X, He L, Han J, Wang L, et al
    Association of neutrophil-lymphocyte ratio and T lymphocytes with the pathogenesis and progression of HBV-associated primary liver cancer.
    PLoS One. 2017;12:e0170605.
    PubMed     Abstract available

  220. ZHANG BB, Yan C, Fang F, Du Y, et al
    Increased hepatic Th2 and Treg subsets are associated with biliary fibrosis in different strains of mice caused by Clonorchis sinensis.
    PLoS One. 2017;12:e0171005.
    PubMed     Abstract available

  221. SALDANA RS, Schrem H, Barthold M, Kaltenborn A, et al
    Prognostic Abilities and Quality Assessment of Models for the Prediction of 90-Day Mortality in Liver Transplant Waiting List Patients.
    PLoS One. 2017;12:e0170499.
    PubMed     Abstract available

  222. WANG L, Feng Y, Ma X, Wang G, et al
    Diagnostic efficacy of noninvasive liver fibrosis indexes in predicting portal hypertension in patients with cirrhosis.
    PLoS One. 2017;12:e0182969.
    PubMed     Abstract available

  223. LE MH, Devaki P, Ha NB, Jun DW, et al
    Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States.
    PLoS One. 2017;12:e0173499.
    PubMed     Abstract available

  224. GARDINALI NR, Guimaraes JR, Melgaco JG, Kevorkian YB, et al
    Cynomolgus monkeys are successfully and persistently infected with hepatitis E virus genotype 3 (HEV-3) after long-term immunosuppressive therapy.
    PLoS One. 2017;12:e0174070.
    PubMed     Abstract available

  225. STAHMEYER JT, Rossol S, Liersch S, Guerra I, et al
    Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.
    PLoS One. 2017;12:e0169401.
    PubMed     Abstract available

  226. KJAERGAARD M, Thiele M, Jansen C, Staehr Madsen B, et al
    High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie meal.
    PLoS One. 2017;12:e0173992.
    PubMed     Abstract available

  227. KOMIYAMA Y, Kurosaki M, Nakanishi H, Takahashi Y, et al
    Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.
    PLoS One. 2017;12:e0174649.
    PubMed     Abstract available

  228. DIJKSTRA H, Wolff D, van Melle JP, Bartelds B, et al
    Diminished liver microperfusion in Fontan patients: A biexponential DWI study.
    PLoS One. 2017;12:e0173149.
    PubMed     Abstract available

  229. LEE SM, Lee JM, Kang HJ, Yang HK, et al
    Liver fibrosis staging with a new 2D-shear wave elastography using comb-push technique: Applicability, reproducibility, and diagnostic performance.
    PLoS One. 2017;12:e0177264.
    PubMed     Abstract available

  230. ROKUSZ A, Veres D, Szucs A, Bugyik E, et al
    Ductular reaction correlates with fibrogenesis but does not contribute to liver regeneration in experimental fibrosis models.
    PLoS One. 2017;12:e0176518.
    PubMed     Abstract available

  231. YANG KL, Chang WT, Hong MY, Hung KC, et al
    Prevention of TGF-beta-induced early liver fibrosis by a maleic acid derivative anti-oxidant through suppression of ROS, inflammation and hepatic stellate cells activation.
    PLoS One. 2017;12:e0174008.
    PubMed     Abstract available

  232. KRAWCZYK M, Zimmermann S, Hess G, Holz R, et al
    Panel of three novel serum markers predicts liver stiffness and fibrosis stages in patients with chronic liver disease.
    PLoS One. 2017;12:e0173506.
    PubMed     Abstract available

  233. SONG YN, Dong S, Wei B, Liu P, et al
    Metabolomic mechanisms of gypenoside against liver fibrosis in rats: An integrative analysis of proteomics and metabolomics data.
    PLoS One. 2017;12:e0173598.
    PubMed     Abstract available

  234. KONDILI LA, Gaeta GB, Ieluzzi D, Zignego AL, et al
    Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.
    PLoS One. 2017;12:e0172159.
    PubMed     Abstract available

  235. JOLY P, Vignaud H, Di Martino J, Ruiz M, et al
    ERAD defects and the HFE-H63D variant are associated with increased risk of liver damages in Alpha 1-Antitrypsin Deficiency.
    PLoS One. 2017;12:e0179369.
    PubMed     Abstract available

  236. NAKAMURA M, Kanda T, Jiang X, Haga Y, et al
    Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein are useful tools for liquid biopsy of the patients with hepatitis B virus and advanced liver fibrosis.
    PLoS One. 2017;12:e0177302.
    PubMed     Abstract available

  237. LAI LL, Chan WK, Sthaneshwar P, Nik Mustapha NR, et al
    Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in non-alcoholic fatty liver disease.
    PLoS One. 2017;12:e0174982.
    PubMed     Abstract available

  238. DOLD L, Luda C, Schwarze-Zander C, Boesecke C, et al
    Genetic polymorphisms associated with fatty liver disease and fibrosis in HIV positive patients receiving combined antiretroviral therapy (cART).
    PLoS One. 2017;12:e0178685.
    PubMed     Abstract available

  239. KRAUSKOPF J, de Kok TM, Schomaker SJ, Gosink M, et al
    Serum microRNA signatures as "liquid biopsies" for interrogating hepatotoxic mechanisms and liver pathogenesis in human.
    PLoS One. 2017;12:e0177928.
    PubMed     Abstract available

  240. LIN WC, Lin HH, Hung CY, Shih SC, et al
    Clinical endoscopic management and outcome of post-endoscopic sphincterotomy bleeding.
    PLoS One. 2017;12:e0177449.
    PubMed     Abstract available

  241. MOQUEET N, Kanagaratham C, Gill MJ, Hull M, et al
    A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection.
    PLoS One. 2017;12:e0176282.
    PubMed     Abstract available

  242. WONG MW, Chen MJ, Chen HL, Kuo YC, et al
    Application of chronic liver failure-sequential organ failure assessment score for the predication of mortality after esophageal variceal hemorrhage post endoscopic ligation.
    PLoS One. 2017;12:e0182529.
    PubMed     Abstract available

  243. KIM G, Kim KJ, Rhee Y, Lim SK, et al
    Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease.
    PLoS One. 2017;12:e0182202.
    PubMed     Abstract available

  244. CAI G, Chen B, Li Z, Wei W, et al
    The different expressed serum proteins in rhCygb treated rat model of liver fibrosis by the optimized two-dimensional gel electrophoresis.
    PLoS One. 2017;12:e0177968.
    PubMed     Abstract available

  245. GUPTA N, Kabahizi J, Mukabatsinda C, Walker TD, et al
    "Waiting for DAAs": A retrospective chart review of patients with untreated hepatitis C in Rwanda.
    PLoS One. 2017;12:e0174148.
    PubMed     Abstract available

  246. CHANG JY, Kim SE, Kim TH, Woo SY, et al
    Emergence of rifampin-resistant staphylococci after rifaximin administration in cirrhotic patients.
    PLoS One. 2017;12:e0186120.
    PubMed     Abstract available

  247. LEVENTER-ROBERTS M, Hammerman A, Brufman I, Hoshen M, et al
    Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study.
    PLoS One. 2017;12:e0176858.
    PubMed     Abstract available

  248. PRESTIGIACOMO V, Weston A, Messner S, Lampart F, et al
    Pro-fibrotic compounds induce stellate cell activation, ECM-remodelling and Nrf2 activation in a human 3D-multicellular model of liver fibrosis.
    PLoS One. 2017;12:e0179995.
    PubMed     Abstract available

  249. LE CORVEC M, Jezequel C, Monbet V, Fatih N, et al
    Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis.
    PLoS One. 2017;12:e0185997.
    PubMed     Abstract available

  250. SAGNELLI C, Uberti-Foppa C, Hasson H, Bellini G, et al
    Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients.
    PLoS One. 2017;12:e0181890.
    PubMed     Abstract available

  251. ROSINSKA M, Parda N, Kolakowska A, Godzik P, et al
    Factors associated with hepatitis C prevalence differ by the stage of liver fibrosis: A cross-sectional study in the general population in Poland, 2012-2016.
    PLoS One. 2017;12:e0185055.
    PubMed     Abstract available

  252. GOMEZ-MORENO AZ, Pineda-Tenor D, Jimenez-Sousa MA, Sanchez-Ruano JJ, et al
    Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study.
    PLoS One. 2017;12:e0184404.
    PubMed     Abstract available

  253. LI J, Ghazwani M, Liu K, Huang Y, et al
    Regulation of hepatic stellate cell proliferation and activation by glutamine metabolism.
    PLoS One. 2017;12:e0182679.
    PubMed     Abstract available

  254. KIM G, Kang SH, Kim MY, Baik SK, et al
    Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0186990.
    PubMed     Abstract available

  255. UEMURA H, Tsukada K, Mizushima D, Aoki T, et al
    Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
    PLoS One. 2017;12:e0186255.
    PubMed     Abstract available

  256. GARCIA-GARCIA R, Cruz-Gomez AJ, Mangas-Losada A, Urios A, et al
    Reduced resting state connectivity and gray matter volume correlate with cognitive impairment in minimal hepatic encephalopathy.
    PLoS One. 2017;12:e0186463.
    PubMed     Abstract available

  257. BHAT M, Tazari M, Sebastiani G
    Performance of transient elastography and serum fibrosis biomarkers for non-invasive evaluation of recurrent fibrosis after liver transplantation: A meta-analysis.
    PLoS One. 2017;12:e0185192.
    PubMed     Abstract available

  258. MAROT A, Henrion J, Knebel JF, Moreno C, et al
    Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study.
    PLoS One. 2017;12:e0186715.
    PubMed     Abstract available

  259. FRIEDRICH-RUST M, Schoelzel F, Maier S, Seeger F, et al
    Severity of coronary artery disease is associated with non-alcoholic fatty liver dis-ease: A single-blinded prospective mono-center study.
    PLoS One. 2017;12:e0186720.
    PubMed     Abstract available

  260. KARTOUN U, Corey KE, Simon TG, Zheng H, et al
    The MELD-Plus: A generalizable prediction risk score in cirrhosis.
    PLoS One. 2017;12:e0186301.
    PubMed     Abstract available

  261. HUBER W, Gruber A, Eckmann M, Elkmann F, et al
    Comparison of pulmonary vascular permeability index PVPI and global ejection fraction GEF derived from jugular and femoral indicator injection using the PiCCO-2 device: A prospective observational study.
    PLoS One. 2017;12:e0178372.
    PubMed     Abstract available

  262. KEATING SM, Dodge JL, Norris PJ, Heitman J, et al
    The effect of HIV infection and HCV viremia on inflammatory mediators and hepatic injury-The Women's Interagency HIV Study.
    PLoS One. 2017;12:e0181004.
    PubMed     Abstract available

  263. YE Y, Li Z, Feng Q, Chen Z, et al
    Downregulation of microRNA-145 may contribute to liver fibrosis in biliary atresia by targeting ADD3.
    PLoS One. 2017;12:e0180896.
    PubMed     Abstract available

  264. YOKOTA T, Omachi K, Suico MA, Kojima H, et al
    Bromide supplementation exacerbated the renal dysfunction, injury and fibrosis in a mouse model of Alport syndrome.
    PLoS One. 2017;12:e0183959.
    PubMed     Abstract available

  265. ROGAL SS, Udawatta V, Akpan I, Moghe A, et al
    Risk factors for hospitalizations among patients with cirrhosis: A prospective cohort study.
    PLoS One. 2017;12:e0187176.
    PubMed     Abstract available

  266. STROFFOLINI T, Sagnelli E, Andriulli A, Colloredo G, et al
    Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis.
    PLoS One. 2017;12:e0185710.
    PubMed     Abstract available

  267. CHEN YI MEI SLG, Thompson AJ, Christensen B, Cunningham G, et al
    Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection.
    PLoS One. 2017;12:e0185609.
    PubMed     Abstract available

  268. KONERMAN MA, Lu D, Zhang Y, Thomson M, et al
    Assessing risk of fibrosis progression and liver-related clinical outcomes among patients with both early stage and advanced chronic hepatitis C.
    PLoS One. 2017;12:e0187344.
    PubMed     Abstract available

  269. XIAO H, Shi M, Xie Y, Chi X, et al
    Comparison of diagnostic accuracy of magnetic resonance elastography and Fibroscan for detecting liver fibrosis in chronic hepatitis B patients: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0186660.
    PubMed     Abstract available

  270. YINDOM LM, Mendy M, Bodimeade C, Chambion C, et al
    KIR content genotypes associate with carriage of hepatitis B surface antigen, e antigen and HBV viral load in Gambians.
    PLoS One. 2017;12:e0188307.
    PubMed     Abstract available

  271. SANDAHL TD, Stoy SH, Laursen TL, Rodgaard-Hansen S, et al
    The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients.
    PLoS One. 2017;12:e0189345.
    PubMed     Abstract available

  272. LEE MS, Bae JM, Joo SK, Woo H, et al
    Prospective comparison among transient elastography, supersonic shear imaging, and ARFI imaging for predicting fibrosis in nonalcoholic fatty liver disease.
    PLoS One. 2017;12:e0188321.
    PubMed     Abstract available

  273. PINHEIRO D, Leiros L, Dau JBT, Stumbo AC, et al
    Cytokines, hepatic cell profiling and cell interactions during bone marrow cell therapy for liver fibrosis in cholestatic mice.
    PLoS One. 2017;12:e0187970.
    PubMed     Abstract available

  274. ALAZAWI W, Bernabe E, Tai D, Janicki T, et al
    Periodontitis is associated with significant hepatic fibrosis in patients with non-alcoholic fatty liver disease.
    PLoS One. 2017;12:e0185902.
    PubMed     Abstract available

  275. FEIG JL, Mediero A, Corciulo C, Liu H, et al
    The antiviral drug tenofovir, an inhibitor of Pannexin-1-mediated ATP release, prevents liver and skin fibrosis by downregulating adenosine levels in the liver and skin.
    PLoS One. 2017;12:e0188135.
    PubMed     Abstract available

  276. ZHENG XY, Zhao X, Yang YF, Jiang HJ, et al
    Antioxidant, antiapoptotic and amino acid balance regulating activities of 1,7-dihydroxy-3,4,8-trimethoxyxanthone against dimethylnitrosamine-induced liver fibrosis.
    PLoS One. 2017;12:e0189344.
    PubMed     Abstract available

    January 2016
  277. SANSOE G, Aragno M, Mastrocola R, Mengozzi G, et al
    Role of Chymase in the Development of Liver Cirrhosis and Its Complications: Experimental and Human Data.
    PLoS One. 2016;11:e0162644.
    PubMed     Abstract available

  278. HUNG TH, Lay CJ, Tseng CW, Tsai CC, et al
    The Effect of Renal Function Impairment on the Mortality of Cirrhotic Patients: A Nationwide Population-Based 3-Year Follow-up Study.
    PLoS One. 2016;11:e0162987.
    PubMed     Abstract available

  279. SOBREVALS L, Enguita M, Quiroga J, Prieto J, et al
    Insulin-Like Growth Factor I (IGF-I) Expressed from an AAV1 Vector Leads to a Complete Reversion of Liver Cirrhosis in Rats.
    PLoS One. 2016;11:e0162955.
    PubMed     Abstract available

  280. YE Q, Qian BX, Yin WL, Wang FM, et al
    Association between the HFE C282Y, H63D Polymorphisms and the Risks of Non-Alcoholic Fatty Liver Disease, Liver Cirrhosis and Hepatocellular Carcinoma: An Updated Systematic Review and Meta-Analysis of 5,758 Cases and 14,741 Controls.
    PLoS One. 2016;11:e0163423.
    PubMed     Abstract available

  281. LIU TL, Barritt Iv AS, Weinberger M, Paul JE, et al
    Who Treats Patients with Diabetes and Compensated Cirrhosis.
    PLoS One. 2016;11:e0165574.
    PubMed     Abstract available

  282. FJELD K, Beer S, Johnstone M, Zimmer C, et al
    Length of Variable Numbers of Tandem Repeats in the Carboxyl Ester Lipase (CEL) Gene May Confer Susceptibility to Alcoholic Liver Cirrhosis but Not Alcoholic Chronic Pancreatitis.
    PLoS One. 2016;11:e0165567.
    PubMed     Abstract available

  283. FAN WC, Liu CW, Ou SM, Huang CC, et al
    TLR4/CD14 Variants-Related Serologic and Immunologic Dys-Regulations Predict Severe Sepsis in Febrile De-Compensated Cirrhotic Patients.
    PLoS One. 2016;11:e0166458.
    PubMed     Abstract available

  284. DELEURAN T, Vilstrup H, Overgaard S, Jepsen P, et al
    No Increased Risk for Primary Osteoarthritis in Liver Cirrhosis - A Danish Nationwide Cohort Study.
    PLoS One. 2016;11:e0167134.
    PubMed     Abstract available

  285. JEON I, Cho ES, Kim JH, Kim DJ, et al
    Feasibility of 10-Minute Delayed Hepatocyte Phase Imaging Using a 30 degrees Flip Angle in Gd-EOB-DTPA-Enhanced Liver MRI for the Detection of Hepatocellular Carcinoma in Patients with Chronic Hepatitis or Cirrhosis.
    PLoS One. 2016;11:e0167701.
    PubMed     Abstract available

  286. NUNEZ-TORRES R, Macias J, Mancebo M, Frias M, et al
    The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients.
    PLoS One. 2016;11:e0168265.
    PubMed     Abstract available

  287. TUTTOLOMONDO A, Di Raimondo D, Bellia C, Clemente G, et al
    Immune-Inflammatory and Metabolic Effects of High Dose Furosemide plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects with Refractory Ascites.
    PLoS One. 2016;11:e0165443.
    PubMed     Abstract available

  288. SARRAZIN C, Manns M, Calleja JL, Garcia-Samaniego J, et al
    HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment.
    PLoS One. 2016;11:e0168544.
    PubMed     Abstract available

  289. NOVO-VELEIRO I, Cieza-Borrella C, Pastor I, Chamorro AJ, et al
    A Single Nucleotide Polymorphism in the RASGRF2 Gene Is Associated with Alcoholic Liver Cirrhosis in Men.
    PLoS One. 2016;11:e0168685.
    PubMed     Abstract available

  290. GAO Y, Ren H, Meng F, Li J, et al
    Pathological Roles of Interleukin-22 in the Development of Recurrent Hepatitis C after Liver Transplantation.
    PLoS One. 2016;11:e0154419.
    PubMed     Abstract available

  291. YASUI Y, Abe T, Kurosaki M, Higuchi M, et al
    Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma.
    PLoS One. 2016;11:e0154558.
    PubMed     Abstract available

  292. EHLKEN H, Wroblewski R, Corpechot C, Arrive L, et al
    Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis.
    PLoS One. 2016;11:e0164224.
    PubMed     Abstract available

  293. ZHENG S, Zhang P, Chen Y, Zheng S, et al
    Inhibition of Notch Signaling Attenuates Schistosomiasis Hepatic Fibrosis via Blocking Macrophage M2 Polarization.
    PLoS One. 2016;11:e0166808.
    PubMed     Abstract available

  294. AIKEN T, Garber A, Thomas D, Hamon N, et al
    Donor IFNL4 Genotype Is Associated with Early Post-Transplant Fibrosis in Recipients with Hepatitis C.
    PLoS One. 2016;11:e0166998.
    PubMed     Abstract available

  295. PUIGVEHI M, Hernandez J, Broquetas T, Coll S, et al
    Diagnostic Accuracy of the Enhanced Liver Fibrosis (ELF(R)) Score Using HCV-Infected Serum Samples Cryopreserved for up to 25 Years.
    PLoS One. 2016;11:e0164883.
    PubMed     Abstract available

  296. BURKE SCHINKEL SC, Carrasco-Medina L, Cooper CL, Crawley AM, et al
    Generalized Liver- and Blood-Derived CD8+ T-Cell Impairment in Response to Cytokines in Chronic Hepatitis C Virus Infection.
    PLoS One. 2016;11:e0157055.
    PubMed     Abstract available

  297. NGUYEN TRUONG T, Laureillard D, Lacombe K, Duong Thi H, et al
    High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262).
    PLoS One. 2016;11:e0153744.
    PubMed     Abstract available

  298. IBRAHIM MK, Salum GM, Bader El Din NG, Dawood RM, et al
    Transcriptional Dysregulation of Upstream Signaling of IFN Pathway in Chronic HCV Type 4 Induced Liver Fibrosis.
    PLoS One. 2016;11:e0154512.
    PubMed     Abstract available

  299. SHI L, Qin E, Zhou J, Zhao J, et al
    HIV and HCV Co-Culture Promotes Profibrogenic Gene Expression through an Epimorphin-Mediated ERK Signaling Pathway in Hepatic Stellate Cells.
    PLoS One. 2016;11:e0158386.
    PubMed     Abstract available

  300. JURADO-GARCIA J, Munoz Garcia-Borruel M, Rodriguez-Peralvarez ML, Ruiz-Cuesta P, et al
    Impact of MELD Allocation System on Waiting List and Early Post-Liver Transplant Mortality.
    PLoS One. 2016;11:e0155822.
    PubMed     Abstract available

  301. AMORAS EDA S, Gomes ST, Freitas FB, Santana BB, et al
    Intrahepatic mRNA Expression of FAS, FASL, and FOXP3 Genes Is Associated with the Pathophysiology of Chronic HCV Infection.
    PLoS One. 2016;11:e0156604.
    PubMed     Abstract available

  302. ZHANG YH, Zhao Y, Rajapaksa US, Lawrence TM, et al
    A Comprehensive Analysis of the Impact of HIV on HCV Immune Responses and Its Association with Liver Disease Progression in a Unique Plasma Donor Cohort.
    PLoS One. 2016;11:e0158037.
    PubMed     Abstract available

  303. LIN MV, Sise ME, Pavlakis M, Amundsen BM, et al
    Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
    PLoS One. 2016;11:e0158431.
    PubMed     Abstract available

  304. EMBADE N, Marino Z, Diercks T, Cano A, et al
    Metabolic Characterization of Advanced Liver Fibrosis in HCV Patients as Studied by Serum 1H-NMR Spectroscopy.
    PLoS One. 2016;11:e0155094.
    PubMed     Abstract available

  305. CHEKURI S, Nickerson J, Bichoupan K, Sefcik R, et al
    Liver Stiffness Decreases Rapidly in Response to Successful Hepatitis C Treatment and Then Plateaus.
    PLoS One. 2016;11:e0159413.
    PubMed     Abstract available

  306. PELUSI S, Petta S, Rosso C, Borroni V, et al
    Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease.
    PLoS One. 2016;11:e0163069.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.